ABSTRACT
Introduction
TB remains one of the leading causes of global morbidity and mortality among infectious diseases largely because of HIV pandemics and multidrug-resistant TB [1] . TP represents one of the most common forms of extrapulmonary TB and often results from Mtb infection of the pleura, with an intensive accumulation of immune cells in the pleural space [2] [3] [4] . Our studies and those of others [5] [6] [7] [8] [9] [10] [11] have shown that CD4 + and CD8 + T cells have a role in immunity against Mtb infection. Our recent studies [12] [13] [14] also show that Mtb phosphoantigen-specific Vg2Vd2 T cells, which exist only in primates, also have a role in immune resistance to TB. IFN-g and TNF-a produced by ab CD4 + /CD8 + and gd T cells have been shown to be critical for controlling Mtb infection [5] [6] [7] [8] [9] [10] [11] . However, overproduction of IFN-g and TNF-a by CD4 + + T regs . T regs have been shown to suppress T cells and APCs in vitro and to inhibit transplant rejection and autoimmune reaction in vivo [15, 16] . Although T regs undergo expansion during human TB [17] [18] [19] [20] , the in vivo roles of T regs and their effects on responses of ab CD4 + /CD8 + and gd T cells remain incompletely understood in human TB or TP. It is generally presumed that TP reflects a delayed hypersensitivity response to mycobacterial antigens in the pleural space, with consequent pleural effusion. Although several groups have reported that T regs are increased in patients with TP [21] [22] [23] [24] [25] , studies have not investigated a detailed correlation between T regs and ab CD4 + /CD8 + and gd T cells in respective pleural and airway or lung compartments or the dynamic changes in these T effector subpopulations after anti-TB chemotherapy. Importantly, although T cells are most frequently found in TP fluid [3] , there is no in vivo evidence indicating that hypothetical, overreactive T cells in the pleural compartment produce large amounts of proinflammatory cytokines [26] [27] [28] . One of the reasons for this might be due to a lack of optimal and timely assays catching effector function for producing cytokines by pleural lymphocytes. T cells that have undergone trafficking/accumulating in pleural space may be highly activated effector cells with "terminated" phenotypes, and conventional ICS after in vitro Ag stimulation may not optimally detect effector function for producing cytokines by these pleural T cells. In addition, the inflammatory nature of pleural effusion fluid may predispose immune cells/cytokine proteins to disadvantageous viability/detectability, making it difficult to detect by conventional ICS after Ag stimulation.
In the current study, we used direct ICS 
MATERIALS AND METHODS

Ethics statement
All samples were collected with informed, written consent, according to protocols approved by the internal review and the ethics boards of Guangdong Medical College.
Patients
Twenty-one patients with TP, from 22 to 60 yr old, and 18 healthy individuals, from 20 to 55 yr old, were used in this study (Supplemental Table 1 ). TP subjects were inpatients of the pulmonary departments of the Affiliated Hospital of Guangdong Medical College, the Affiliated Houjie Hospital of Guangdong Medical College, and the Dongguan Hospital for Prophylaxis and Treatment of Chronic Disease. TP was confirmed based on typical clinical symptoms, chest X-radiography with no evidence of lung TB lesions, positive Ziehl-Neelsen acid fast bacilli staining, positive Lowenstein-Jensen slants bacterial culture for pleural fluid sediments, or pleural membrane biopsies or apparent anti-TB drugs efficacy. Bronchoscopy was performed to confirm a lack of evidence for respiratory diseases, lesions, or tumors and to collect BAL fluid. Subject exclusion criteria included HIV + test results, diabetes, cancer, autoimmune diseases, immunosuppressive treatment, or previous pulmonary TB. All blood, pleural effusion fluid, or BAL samples were collected before or within ;1 wk before the patients received anti-TB drugs of individualized isoniazid, rifampicin, pyrazinamide, and ethambutol. All patients responded well to anti-TB chemotherapy, with apparent clinical improvement before discharge. The 18 healthy, uninfected individuals served as controls.
Preparation of PBMC and lymphocytes from PE or BAL fluid
These methods were described in details elsewhere [13, 32] . Briefly, PBMC and lymphocytes were isolated from fresh blood and pleural effusion, respectively, by standard Ficoll (GE Healthcare, Little Chalfont, United Kingdom) density gradient centrifugation. For isolation of lymphocytes from BAL fluid, fresh BAL fluid was filtered through 20 ml of 2% FBS-PBS into 50 ml tubes followed by 5 min 3 1500 rpm centrifugation. Cell pellets were then treated with 5 ml RBC blood lysis buffer (eBioscience, San Diego, CA, USA) for 10 min or until the suspension became clear and washed once with 2% FBS-PBS. Isolated lymphocytes were stained with trypan blue to identify the viability and to enumerate cell counts.
Antibodies and reagents
The 
ICS
ICS was performed as previously described (13, 32) . Lymphocytes (3;10 3 10 5 ) were incubated for 6 h in the absence or presence of HMBPP (40 ng/ml) medium, purified protein derivative (20 mg/ml), and PMA, plus costimulatory CD28 (1 mg/ml) and CD49d (1 mg/ml) mAbs. After 6 h incubation, cells were transferred into 5 ml polystyrene, round-bottom tubes (BD Biosciences) for staining. Cells were washed once with 2% FBS-PBS and stained at room temperature for 25 min with surface marker Abs. For ICS, PBMCs were further washed twice with 2% FBS-PBS and permeabilized with BD FACS permeabilizing solution (BD Biosciences) for 30 min at room temperature, and then stained for another 45 min with IFN-g and IL-22 Abs, followed by 2 final washes with 2% FBS-PBS buffer and analysis with BD FACSCanto II (BD Biosciences) flow cytometry. To ensure specific immune staining in ICS, matched isotype IgG served as negative controls for staining cytokines or surface markers. Direct ICS was used for measuring T effs producing cytokines without in vitro antigen stimulation, as we recently described [9, 13, [29] [30] [31] [32] .
CFSE proliferation assay
PBMCs were stained with fluorescence-labeled antibodies against CD3, CD4, CD25, and CD127 and sorted into CD25 + CD127 2 T regs and CD25
low/2 CD127 + T effs using a BD FACSAria II cell sorter (BD Biosciences). Sorted T regs and T effs were further characterized by intracellular staining with Foxp3. T effs were then labeled with 20 mM of CFSE (Beyotime, Shanghai, China) for 10 min at 37°C and protected from light, which was followed by 3 washes to remove the excess CFSE.
After that, CFSE-labeled T effs (1 3 10 4 ) were cocultured with or without T regs (1 3 10 4 ) in the presence or absence of anti-CD3/CD28 mAbs and cultured for 3 d at 37°C with 5% CO 2 . The CFDA intensity of the gated cells was measured through a 518 nm filter (FL1) with a BD FACS Canto II flow cytometry, and the proliferation index (average number of cell divisions) and percentage of proliferation (cells that divided at least once) were analyzed and calculated by FlowJo.7.6.1 software (Tree Star, Ashland, OR, USA).
Statistical analysis
The normality evaluation was first performed to determine whether the data set was well-modeled with a normal distribution. If data passed the normality distribution evaluation, Student's t test was used for 2-tailed comparisons; if data did not pass the normality, a Mann-Whitney U test was employed, as previously described [13, 32] using GraphPad Prism version 5.0 (GraphPad Software, La Jolla, CA, USA). Results are expressed as means 6 SEM In all cases, P , 0.05 was considered as statistically significant.
RESULTS
Patients with TP exhibit appreciable numbers of airway "proliferating" Vg2Vd2 T cells when Foxp3 + T cells are not dominant
Comparative studies of Mtb-reactive gd T and T regs in the blood, PE, and alveoli or airway in patients with TP have not previously been reported. Here, we comparatively measured the frequencies of Foxp3 + T cells and Vg2Vd2 T cells in PBMC, pleurisy lymphocytes in PE, and alveoli cells in BALF from patients with TP using flow cytometry. The flow cytometry gating strategy is shown in Supplemental Figure 1 . Representative flow cytometry diagrams are shown in Fig. 1A . Interestingly, percentages of Vg2Vd2 T cells in PE appeared lower than those in BALF and blood (Fig. 1A and B) , although there were no apparent differences in the frequencies of blood Vg2Vd2 T cells between patients with TP and HV controls (Fig. 1B) . Notably, when Ki-67 expression was measured as a surrogate marker for cellular proliferation of Vg2Vd2 T cells, patients with TP had fewer blood Ki-67 + Vg2Vd2 T cells than did HV controls (Fig. 1C) . However, Ki-67 + Vg2Vd2 T cells in the airway were significantly higher than those in blood and PE lymphocytes in patients with TP (P , 0.001; Fig. 1C Fig. 2 ). In fact, the frequencies of T regs in the blood of patients with TP were significantly higher than those in HV controls, with up to 50% Foxp3 + cells in CD4 + CD25 + T cells (Fig. 1D ). Control patients + T regs and ;5% Vg2Vd2 T cells in total circulating T cells (data not shown). When we compared T regs in different compartments from patients with TP, we found that frequencies of T regs in the blood and PE were significantly higher than those in the BALF (P , 0.01 and P , 0.001, respectively; Fig. 1D ).
Thus 
CD4
+ T cells in patients with TP. Representative flow diagrams are shown in Fig. 2A . Interestingly, after anti-TB chemotherapy, the frequencies of blood Foxp3 + T cells from patients with TP decreased significantly to levels comparable to those in HV controls ( Fig. 2A and B) . Despite no significant alterations in nonreplicating gd T cells in the blood of these patients with TP after treatment (Fig. 2C) , we found significant increases in the frequencies of proliferating Ki-67 + Vg2Vd2 T cells in the blood 1 mo after treatment (Fig. 2D) + T cells displayed effector functions for production of selected inflammatory cytokines. We focused on IFN-g and IL-22 because these 2 cytokines can either function as anti-TB elements [33, 34] or act as proinflammatory cytokines [35] . We examined the effector responses of Vg2Vd2 T cells and CD4 + /CD8 + T cells using direct intracellular staining without antigen stimulation. PBMC or cells isolated from the PE of patients with TP were directly stained for cytokines without antigen stimulation in vitro, as we recently described [9, 13, [29] [30] [31] [32] , to examine the ability of T cells to constitutively produce IFN-g or IL-22.
We have validated the specificity and utility of the direct ICS approach during Mtb infection of macaques and humans [9, 13, [29] [30] [31] [32] . To facilitate detection, we examined CD25 coexpression in CD3/CD4 or CD3/CD8 for constitutive cytokine production because CD25 + CD4 + /CD8 + T cells were supposed to be activated cells. We first investigated whether these cells were constitutive IL-22-producing T effector subpopulations in patients with TP, as we previously found in the setting of severe TB [29, 34] . We found that Vg2Vd2 T effector cells constitutively producing IL-22 without in vitro HMBPP stimulation were measurable in the blood of patients with TP and were higher than those in HV controls (Fig. 3A and B) , with similar frequencies in the blood and pleurisy compartments of patients with TP (Fig. 3B) . At 1 mo after treatment, we observed a reduction in the percentages of IL-22 + Vg2Vd2 T cells (Fig. 3C) . CD4 + CD25 + and CD8 + CD25 + T cell subpopulations in patients with TP contained low frequencies of constitutively IL-22 + effector cells in either the blood and pleurisy compartments (Fig. 3D) and exhibited no apparent changes at 1 mo after treatment (Fig. 3E) the blood circulation were ;8, 10.5, and 10%, respectively, which were significantly higher than those in HV controls ( Fig. 4A-E) . In control patients with intraparenchymal TB, means of ;6% Vg2Vd2 T cells and means of ;5% CD25 + CD4
+ T cell subpopulation in the blood could constitutively produce IFN-g (data not shown). Surprisingly, despite high-levels of Foxp3 + T cells, the mean percentages of T effs that constitutively produced IFN-g within these 3 T cell subpopulations in the pleurisy compartment were significantly higher than those in the blood circulation (Fig. 4A,  B, and D) . Approximately 18% of Vg2Vd2 + T cell subset in PE lymphocytes from patients with TP could constitutively produce IFN-g without the need for antigen stimulation (Fig.  4B ), although frequencies of these gd T effs were lower than those within CD4 + CD25 + and CD8 + CD25 + T cell subpopulations in PE lymphocytes from patients with TP ( Fig. 4B and D) . Interestingly, at 1 mo after treatment, the percentages of constitutively IFN-g-producing effector cells within Vg2Vd2, CD4 + CD25 + and CD8 + CD25 + T cell subpopulations were sustained and somewhat increased ( Fig. 4C and E) . These shortterm increases could be explained by anti-TB chemotherapydriven improvement of both the presumably activated CD25 + T subset and the Vg2Vd2 + T cell subpopulation comprising both activated and nonactivated cells. These results suggest that T effs constitutively producing IFN-g are engaged by Mtb antigens in vivo in association with delayed hypersensitivity syndrome (fever and pleurisy/breathing compromise).
Thus, TP induced large numbers of constitutive IFNg-producing Vg2Vd2, CD4 + CD25 + and CD8 + CD25 + T effector subpopulations despite high levels of Foxp3 + T cells, and constitutive T effs were sustained even after T regs declined to within reference range at 1 mo after treatment.
DISCUSSION
The current work extends our previous studies of T eff response in primate TB to the setting of patients with TP and demonstrates and elevated IFN-g levels [27, 28] in PE fluid. The sustained T eff responses at 1 mo after the TB treatment do not appear to be attributable to a coincidence of TB lesions and the effusion because repeated chest X-ray tests did not detect any lung TB lesions with negative acid-fast staining in the BAL fluid. [36] , and vaccination against the coinfection-induced attenuation of these highly reactive Th1 responses leads to protection against fatal malaria in primates [37] . Dynamic changes in Foxp3 + T cells suggest they are responsive to TP, rather than dysfunctional. Although earlier studies reported TB-driven increases in T regs in TP [21] [22] [23] [24] [25] and their ability to inhibit immune cells in vitro [17] [18] [19] [20] , our study extends previous findings by demonstrating that the frequencies of Foxp3 + T cells in BALF are much lower than those in the blood and PE of patients with TP. Whether this is due to antagonizing effect from Vg2Vd2 T cells remains unknown. Moreover, 1 mo anti-TB chemotherapy can control TP and reduce Foxp3 + T cells to within reference range. These results suggest that remarkable increases in Foxp3 + T cells might respond to a TB-induced high inflammatory reaction in pleural compartments, but not in the airways if no TB lesions are present in the lungs. The scenario that increases in Foxp3 + T cells respond to the initial high reaction to pleural TB in the host may help explain why increased Foxp3 + T cells fail to influence the robust, constitutive T eff response or prevent pleural inflammation/effusion in patients with TP.
Thus, our study provides previously undescribed findings, and data support our hypothesis that TP appears to be characterized by a highly reactive host response involving large numbers of T eff subpopulations constitutively producing 1 or more proinflammatory cytokines, and provided reagents and protocols, and gave scientific advice while evaluating and discussing data.
